Perioperative medicine & outcomes
Perioperative discontinuation of SGLT2-inhibitors and cardiac complications after noncardiac surgery: secondary analysis of two prospective observational cohort studies
Primary result · Cardiovascular complicationsResult — go to the resultAdjusted odds ratio 1.58 95% CI 1.08–2.30Authors' conclusion
Perioperative SGLT2i discontinuation was associated with a substantially increased risk of 90-day cardiac complications.
Study context
- Population
- Participants receiving chronic SGLT2i therapy undergoing major noncardiac surgery393 (87.1%) discontinued
- Participants
- 451 participants
- Comparison
- Continuing vs stopping SGLT2i before surgery
- Continuedn = 58reference
- 1 dayn = 177
- 2 daysn = 155
- ≥3 daysn = 61
- Primary endpoint
- Ordinal composite of:
- Acute HF hospitalisation
- Cardiovascular death
- Follow-up
- Within 90 days of surgery
Methodological detailsBasel-PMI and PMI-Vital, adjusted for prespecified covariates
- Basel-PMI and PMI-Vital
- Adjusted for prespecified covariates
Primary result
Cardiovascular complications · 90 days
Adjusted odds ratio
1.58
95% CI 1.08–2.30
P = 0.011
Events by treatment group
Per discontinued day
aOR 1.58 (95% CI 1.08–2.30); P = 0.011
Per discontinued day, as printed
As reported in the abstract
Safety
Euglycemic diabetic ketoacidosis after SGLT2i discontinuation · within 7 days
- Euglycemic diabetic ketoacidosis occurred after SGLT2i discontinuation
- 1/451
Original publication
Perioperative discontinuation of SGLT2-inhibitors and cardiac complications after noncardiac surgery: secondary analysis of two prospective observational cohort studies. Br J Anaesth. Published 11 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →